• Citer

Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in advanced squamous cell carcinoma of the head and neck

par Rozencweig, Marcel ;Dalesio, Otllla;Van Rijmenant, Marcel ;Dodion, Pierre ;Bruntsch, Uta;Gallmeier, Walter Michael W.;Clavel, Michel;Gignoux, B.;Cortes-Funes, Hernan;Cavalli, Franc0;Kirkpatrick, Anne
Référence Cancer, 54, 8, page (1499-1503)
Publication Publié, 1984

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

A combination of cisplatin, methotrexate, bleomycin, and vincristine (CABO) was assessed in advanced epidermoid head and neck cancer. Among 72 patients with recurrent or metastatic disease and measurable lesions, there were 9 complete and 27 partial responses for an overall response rate of 50%. These results were adversely affected by prior surgery plus prior radiotherapy. The median response duration was 28 weeks (16‐l00+) in complete responders and 16 weeks (6‐84) in partial responders. CABO was also administered to 56 patients with measurable, previously untreated, locoregional disease. In these patients, complete and partial response rates were 18% and 46%, respectively. Toxic effects were generally mild to moderate. In spite of its encouraging therapeutic efficacy, CABO is unlikely to be clearly superior to single‐agent chemotherapy, at least in recurrent or disseminated disease. Increased effectiveness of CABO given as initial treatment suggests that chemotherapy might play an effective adjuvant role in carefully selected patients. Copyright © 1984 American Cancer Society